Physician profile
Lee E Sheinkopf
NPI 1811085871
$16,561.60
in general payments reported to CMS, 2019-2025
39 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,233 · 2020: $1,220 · 2021: $2,312 · 2022: $3,269 · 2023: $2,659 · 2024: $2,402 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,384 · Consulting Fee: $78.21 · Education: $66.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,383.60 |
| Consulting Fee | $78.21 |
| Education | $66.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,978.54 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,887.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $1,754.00 | 2021-2025 | Tezspire, Actimmune |
| Genzyme Corporation | $1,664.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,554.62 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Pharming Healthcare, INC. | $882.59 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $768.35 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Grifols USA, LLC | $652.65 | 2019-2025 | Xembify |
| Csl Behring | $629.04 | 2019-2025 | Hizentra |
| Octapharma USA, INC. | $567.79 | 2019-2023 | Cutaquig, Panzyga |
| Novartis Pharmaceuticals Corporation | $447.18 | 2019-2025 | |
| Pfizer INC. | $427.49 | 2019-2025 | |
| Genentech USA, INC. | $409.60 | 2019-2025 | Xolair |
| Optinose US, INC. | $394.70 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.58 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $308.96 | 2019-2024 | Auvi-Q |
| Mylan Specialty L.P. | $233.27 | 2019-2024 | Yupelri |
| Alk-Abello, INC | $177.72 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Abbvie INC. | $177.01 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $171.59 | 2019-2021 | |
| Leo Pharma INC. | $167.86 | 2022-2025 | Adbry, Anzupgo |
| Blueprint Medicines Corporation | $110.52 | 2023-2024 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $90.77 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $78.54 | 2019-2025 | |
| Adma Biomanufacturing LLC | $78.21 | 2024-2025 | |
| Viatris Specialty LLC | $71.60 | 2025 | Yupelri |
| Bio Products Laboratory USA, INC. | $68.55 | 2020-2023 | Coagadex, Gammaplex |
| Incyte Corporation | $65.19 | 2023-2025 | Opzelura |
| Gc Biopharma USA, INC. | $55.08 | 2025 | Alyglo |
| Phadia US INC. | $54.10 | 2020-2024 | Immunocap |
| Greer Laboratories, INC. | $52.30 | 2025 | Oralair |
| Electromed, INC. | $46.32 | 2022-2023 | Smartvest |
| Horizon Therapeutics Plc | $41.34 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $40.38 | 2024 | Ryaltris |
| Shire North American Group INC | $38.33 | 2019 | |
| Galderma Laboratories, L.P. | $22.89 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $18.12 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.47 | 2019 | |
| Covis Pharma Gmbh | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Sheinkopf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.